The DOI matches its OpenAlex record.
Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.
Abstract
Whereas the impact of early (first 6 postoperative weeks) acute cellular rejection on patient survival among liver transplant recipients as a whole has been reported to be favorable, we hypothesized treatment for acute cellular rejection may have differing impacts on patient and graft survival in hepatitis C virus (HCV)-infected and HCV-negative transplant recipients. We studied the impact of immunosuppression and rejection on patient and graft survival among the 166 HCV-infected and 602 HCV-negative transplant recipients enrolled onto the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. All data were collected prospectively. The association of early acute cellular rejection with mortality was determined using a Cox proportional hazards model with a time-dependent covariate. Median follow-up was 5.0 years for HCV-infected and 5.2 years for HCV-negative transplant recipients. HCV-infected transplant recipients experienced similar frequencies of acute cellular and steroid-resistant rejection as patients undergoing liver transplantation for most other indications. The mortality risk was significantly increased (relative risk = 2.4; P =.03) for HCV-infected transplant recipients who developed early acute cellular rejection compared with HCV-negative transplant recipients. None of the HCV-infected transplant recipients developed allograft failure secondary to chronic rejection. The choice of calcineurin inhibitor did not affect posttransplantation outcomes. Early acute cellular rejection occurs at similar frequencies in HCV-infected and HCV-negative transplant recipients. Although an episode of early acute cellular rejection is associated with a lower cumulative mortality among HCV-negative transplant recipients, the opposite is true for HCV-infected transplant recipients, who experience an increased risk for mortality after an episode of early acute cellular rejection. The adverse impact of early acute cellular rejection on patient survival should be considered in developing primary immunosuppression and acute cellular rejection treatment protocols for HCV-infected transplant recipients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wiesner, R., Rabkin, J., Klintmalm, G., McDiarmid, S., Langnas, A., Punch, J., McMaster, P., Kalayoglu, M., Levy, G., Freeman, R., et al. (2001) · Liver Transplantation · doi:10.1053/jlts.2001.23356 · Cited by 278
Acute Rejection Increases Risk of Graft Failure and Death in Recent Liver Transplant Recipients
Levitsky, J., Goldberg, D., Smith, A. R., Mansfield, S. A., Gillespie, B. W., Merion, R. M., Lok, A. S. F., Levy, G., Kulik, L., Abecassis, M., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.07.035 · Cited by 236
Toby, T. K., Abecassis, M., Kim, K., Thomas, P. M., Fellers, R. T., LeDuc, R. D., Kelleher, N. L., Demetris, J., & Levitsky, J. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14359 · Cited by 42
Prediction of Liver Transplant Rejection With a Biologically Relevant Gene Expression Signature
Levitsky, J., Kandpal, M., Guo, K., Zhao, L., Kurian, S., Whisenant, T., & Abecassis, M. (2022) · Transplantation · doi:10.1097/tp.0000000000003895 · Cited by 36
“This changed with the institution of calcineurin inhibitor (CNI) therapies that lowered AR rates resulting in significant improvements in graft and patient survival.(1-4) Recent data have however continued to show the impact of AR on survival, stimulating a resurgence of interest in rejection types, management, and ou…”
BackgroundMethodInfluential
Metadata
- Authors
- Charlton, M., & Seaberg, E.
- Venue
- PubMed
- Publisher
- National Institutes of Health
- Published
- 1999-07-01
- Volume
- 5
- Issue
- 4 Suppl 1
- Pages
- S107-14
- OpenAlex
- W142450307
- Cited by
- 180
- References
- 0
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.